MX2019007073A - Inhibidores de moléculas pequeñas de la familia de quinasas jak. - Google Patents

Inhibidores de moléculas pequeñas de la familia de quinasas jak.

Info

Publication number
MX2019007073A
MX2019007073A MX2019007073A MX2019007073A MX2019007073A MX 2019007073 A MX2019007073 A MX 2019007073A MX 2019007073 A MX2019007073 A MX 2019007073A MX 2019007073 A MX2019007073 A MX 2019007073A MX 2019007073 A MX2019007073 A MX 2019007073A
Authority
MX
Mexico
Prior art keywords
kinases
small molecule
molecule inhibitors
jak family
methods
Prior art date
Application number
MX2019007073A
Other languages
English (en)
Inventor
Koudriakova Tatiana
D Kreutter Kevin
Leonard Kristi
C Rizzolio Michele
C Smith Russell
S Tichenor Mark
Wang Aihua
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019007073A publication Critical patent/MX2019007073A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Compuestos de 2-((1r,4r)-4-(imidazo[4,5-d]pirrolo[2,3-b]piridina-1 (6H)- il)ciclohexil)acetonitrilo, composiciones farmaceuticas que los contienen, metodos de elaboración, y metodos para utilizarlos que incluyen metodos para tratar enfermedades, desordenes y condiciones mediadas por JAK, tales como la enfermedad inflamatoria del intestino.
MX2019007073A 2016-12-16 2017-12-15 Inhibidores de moléculas pequeñas de la familia de quinasas jak. MX2019007073A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662435609P 2016-12-16 2016-12-16
US201762592680P 2017-11-30 2017-11-30
US201762596607P 2017-12-08 2017-12-08
PCT/US2017/066744 WO2018112379A1 (en) 2016-12-16 2017-12-15 Small molecule inhibitors of the jak family of kinases

Publications (1)

Publication Number Publication Date
MX2019007073A true MX2019007073A (es) 2019-10-15

Family

ID=61692222

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022004474A MX2022004474A (es) 2016-12-16 2017-12-15 Inhibidores de moléculas pequeñas de la familia de quinasas jak.
MX2019007073A MX2019007073A (es) 2016-12-16 2017-12-15 Inhibidores de moléculas pequeñas de la familia de quinasas jak.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022004474A MX2022004474A (es) 2016-12-16 2017-12-15 Inhibidores de moléculas pequeñas de la familia de quinasas jak.

Country Status (34)

Country Link
US (5) US10294226B2 (es)
EP (2) EP3555097B1 (es)
JP (2) JP7291077B2 (es)
KR (1) KR102352462B1 (es)
CN (1) CN110088105B (es)
AU (3) AU2017377069B2 (es)
BR (1) BR112019011968A2 (es)
CA (1) CA3046965A1 (es)
CL (1) CL2019001626A1 (es)
CO (1) CO2019006200A2 (es)
CR (1) CR20190282A (es)
DK (1) DK3555097T3 (es)
EC (1) ECSP19042688A (es)
ES (1) ES2922379T3 (es)
HR (1) HRP20220885T1 (es)
HU (1) HUE059274T2 (es)
IL (1) IL267275B (es)
JO (1) JOP20190143B1 (es)
LT (1) LT3555097T (es)
MD (1) MD3555097T2 (es)
MX (2) MX2022004474A (es)
MY (1) MY196260A (es)
NI (1) NI201900060A (es)
PE (1) PE20191105A1 (es)
PH (1) PH12019501254A1 (es)
PL (1) PL3555097T3 (es)
PT (1) PT3555097T (es)
RS (1) RS63500B1 (es)
SA (1) SA519402216B1 (es)
SI (1) SI3555097T1 (es)
TW (1) TWI777997B (es)
UA (1) UA125042C2 (es)
WO (1) WO2018112379A1 (es)
ZA (1) ZA201904615B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019004685A (es) 2016-10-24 2019-08-21 Astrazeneca Ab Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
TW202016110A (zh) * 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US20200338051A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor
KR20220016955A (ko) * 2019-06-06 2022-02-10 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
CN110483514B (zh) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
CA3166743A1 (en) * 2020-02-21 2021-08-26 Weiwei Mao Crystalline form of jak inhibitor and application thereof
CN116925077A (zh) * 2020-09-08 2023-10-24 一又生物(上海)有限公司 吡啶并环类化合物及其制备方法、中间体、组合物和应用
JP2024509587A (ja) 2021-03-11 2024-03-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋ媒介性障害の治療に使用するためのｌｏｒｐｕｃｉｔｉｎｉｂ
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
CN114432317A (zh) * 2021-05-31 2022-05-06 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途
CN113861194B (zh) * 2021-11-10 2022-07-05 英维沃化工科技(广州)有限公司 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
JP5071374B2 (ja) * 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
TW201612182A (en) 2008-06-10 2016-04-01 Abbvie Inc Novel tricyclic compounds
JP2011066747A (ja) * 2009-09-18 2011-03-31 Panasonic Corp 弾性波フィルタ
CN102711476B (zh) 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物
AU2010326030A1 (en) 2009-12-01 2012-06-07 Abbvie Inc. Novel tricyclic compounds
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
AU2011214254B2 (en) 2010-02-10 2016-06-09 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2924026A1 (en) * 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
ES2753159T3 (es) 2015-05-28 2020-04-07 Theravance Biopharma R&D Ip Llc Compuestos de naftiridina como inhibidores de quinasa JAK
WO2017079639A1 (en) 2015-11-04 2017-05-11 Mayo Foundation For Medical Education And Research Methods and materials for treating autoimmune conditions
MX2019004685A (es) 2016-10-24 2019-08-21 Astrazeneca Ab Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
NZ754115A (en) 2016-12-16 2021-07-30 Lilly Co Eli 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
PT3555064T (pt) 2016-12-16 2023-01-20 Pfizer Agonistas dos receptores glp-1 e suas utilizações
WO2018109074A1 (en) 2016-12-16 2018-06-21 Nestec Sa Oligosaccharides for flavour generation
PE20191322A1 (es) 2016-12-16 2019-09-24 Basf Se Compuestos plaguicidas
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
JP7232244B2 (ja) 2017-04-21 2023-03-08 イケナ オンコロジー， インコーポレイテッド インドールａｈｒ阻害剤およびその使用
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US20200338051A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
MX2022004474A (es) 2023-08-15
JP2020502113A (ja) 2020-01-23
IL267275A (en) 2019-08-29
RS63500B1 (sr) 2022-09-30
JOP20190143B1 (ar) 2023-09-17
SI3555097T1 (sl) 2022-09-30
HUE059274T2 (hu) 2022-11-28
PH12019501254A1 (en) 2020-01-20
JP2023071709A (ja) 2023-05-23
LT3555097T (lt) 2022-08-25
AU2020257068A1 (en) 2020-11-19
US20180170931A1 (en) 2018-06-21
US10487083B2 (en) 2019-11-26
ZA201904615B (en) 2021-05-26
MD3555097T2 (ro) 2022-12-31
TWI777997B (zh) 2022-09-21
MY196260A (en) 2023-03-24
CO2019006200A2 (es) 2019-06-28
PT3555097T (pt) 2022-09-22
IL267275B (en) 2021-07-29
AU2017377069B2 (en) 2020-07-23
ECSP19042688A (es) 2019-06-30
EP3555097A1 (en) 2019-10-23
SA519402216B1 (ar) 2022-10-02
CN110088105A (zh) 2019-08-02
ES2922379T3 (es) 2022-09-14
BR112019011968A2 (pt) 2019-11-05
AU2017377069A1 (en) 2019-06-20
PE20191105A1 (es) 2019-08-23
DK3555097T3 (da) 2022-07-25
CN110088105B (zh) 2022-03-18
US10294226B2 (en) 2019-05-21
HRP20220885T1 (hr) 2022-12-09
US20190177322A1 (en) 2019-06-13
JP7291077B2 (ja) 2023-06-14
EP3555097B1 (en) 2022-06-15
KR20190086779A (ko) 2019-07-23
US20190177321A1 (en) 2019-06-13
WO2018112379A1 (en) 2018-06-21
AU2022204240A1 (en) 2022-07-07
UA125042C2 (uk) 2021-12-29
US20190185474A1 (en) 2019-06-20
US11059823B2 (en) 2021-07-13
US10364246B2 (en) 2019-07-30
NI201900060A (es) 2020-03-16
KR102352462B1 (ko) 2022-01-17
AU2022204240B2 (en) 2023-10-05
EP4086256A1 (en) 2022-11-09
CA3046965A1 (en) 2018-06-21
CR20190282A (es) 2019-08-21
PL3555097T3 (pl) 2022-10-17
TW201831180A (zh) 2018-09-01
CL2019001626A1 (es) 2019-10-04
US20210340143A1 (en) 2021-11-04
JOP20190143A1 (ar) 2019-06-13

Similar Documents

Publication Publication Date Title
MX2021011438A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak.
PH12019501254A1 (en) Small molecule inhibitors of the jak family of kinases
MX2020013688A (es) Inhibidores de moleculas peque?as de la familia de quinasas jak.
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201991094A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
MX2015000336A (es) Inhibidores de la enzima fosfodiesterasa 10.
MX2018004517A (es) Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak).
EA201991473A1 (ru) Имидазопирролопиридин в качестве ингибиторов киназ семейства jak
EA201991472A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
IL267801B1 (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
EA202190047A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
CR20190283A (es) Imidazopyrrolopyridine as inhibitors of the jak family of kinases
AR114969A1 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
MA50430B1 (fr) Composés d'imidazo[4,5-d]pyrrolo[2,3-b]pyridine comme inhibiteurs de janus kinases